These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 10718101

  • 1. Pituitary disorders. Drug treatment options.
    Orrego JJ, Barkan AL.
    Drugs; 2000 Jan; 59(1):93-106. PubMed ID: 10718101
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of pituitary adenomas].
    Mezosi E, Nemes O.
    Orv Hetil; 2009 Sep 27; 150(39):1803-10. PubMed ID: 19758960
    [Abstract] [Full Text] [Related]

  • 4. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
    Veldman RG, Frölich M, Pincus SM, Veldhuis JD, Roelfsema F.
    J Clin Endocrinol Metab; 2000 Nov 27; 85(11):4039-46. PubMed ID: 11095430
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec 27; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 6. Clinical review 110: Diagnosis and treatment of pituitary tumors.
    Freda PU, Wardlaw SL.
    J Clin Endocrinol Metab; 1999 Nov 27; 84(11):3859-66. PubMed ID: 10566620
    [Abstract] [Full Text] [Related]

  • 7. Repeat transsphenoidal surgery for Cushing's disease.
    Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB, Loriaux DL.
    J Neurosurg; 1989 Oct 27; 71(4):520-7. PubMed ID: 2552045
    [Abstract] [Full Text] [Related]

  • 8. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
    Losa M, Mortini P, Giovanelli M.
    Minerva Endocrinol; 2003 Mar 27; 28(1):39-51. PubMed ID: 12621362
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun 27; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 10. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan 27; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 11. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.
    Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G, Cantore G.
    Neurol Sci; 2004 Dec 27; 25(5):251-6. PubMed ID: 15624082
    [Abstract] [Full Text] [Related]

  • 12. [Secreting pituitary adenomas].
    Linquette M, Fossati P.
    Rev Prat; 1980 Oct 11; 30(45):3017-8, 3023-6, 3031-2 passim. PubMed ID: 6255550
    [No Abstract] [Full Text] [Related]

  • 13. Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease.
    Storr HL, Afshar F, Matson M, Sabin I, Davies KM, Evanson J, Plowman PN, Besser GM, Monson JP, Grossman AB, Savage MO.
    Eur J Endocrinol; 2005 Jun 11; 152(6):825-33. PubMed ID: 15941921
    [Abstract] [Full Text] [Related]

  • 14. [Medical treatment of secretory hypophyseal adenomas].
    Thomopoulos P.
    Neurochirurgie; 1998 Dec 11; 44(5):309-11. PubMed ID: 9915009
    [Abstract] [Full Text] [Related]

  • 15. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T, Barlier A, Feelders R, Weryha G, Hofland LJ, Ferone D, Gatto F.
    Ann Endocrinol (Paris); 2015 Feb 11; 76(1):43-58. PubMed ID: 25556152
    [Abstract] [Full Text] [Related]

  • 16. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A, Murray RD, Teasdale GM, Shalet SM.
    Clin Endocrinol (Oxf); 2004 Apr 11; 60(4):476-83. PubMed ID: 15049963
    [Abstract] [Full Text] [Related]

  • 17. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
    Rubinfeld H, Hadani M, Barkai G, Taylor JE, Culler MD, Shimon I.
    J Clin Endocrinol Metab; 2006 Jun 11; 91(6):2257-63. PubMed ID: 16595604
    [Abstract] [Full Text] [Related]

  • 18. Plurihormonal ACTH-GH Pituitary Adenoma: Case Report and Systematic Literature Review.
    Roca E, Mattogno PP, Porcelli T, Poliani L, Belotti F, Schreiber A, Maffezzoni F, Fontanella MM, Doglietto F.
    World Neurosurg; 2018 Jun 11; 114():e158-e164. PubMed ID: 29501516
    [Abstract] [Full Text] [Related]

  • 19. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.
    Arafah BM.
    J Clin Endocrinol Metab; 1986 Jun 11; 62(6):1173-9. PubMed ID: 3009521
    [Abstract] [Full Text] [Related]

  • 20. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
    Raverot G, Jouanneau E, Trouillas J.
    Eur J Endocrinol; 2014 Apr 11; 170(4):R121-32. PubMed ID: 24431196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.